Sartorius is strengthening its product portfolio for cell and gene therapies with the acquisition of a majority stake in German reagent manufacturer CellGenix.
Catalent is to acquire German company, RheinCell Therapeutics, a developer and manufacturer of GMP-grade human induced pluripotent stem cells (iPSCs) for the next generation of cell therapies.
The World Health Organization (WHO), as part of its International Nonproprietary Names (INN) system, has recently made progress in developing and harmonizing the definition paragraphs that support the naming of cell-based substances.
Univercells Technologies’ scale-x carbo bioreactor is to be used at the National Institute of Bioprocessing Research and Training (NIBRT) in Dublin, Ireland.
Many turn to Boston and North Carolina’s Research Triangle to set up life science companies, but Chicago is now also fast becoming a draw in this respect. The city is emerging as a life science and biopharma hub and seems poised for even further growth,...
US contract research organization, PPD Inc, is expanding its Athlone, Ireland, GMP laboratory, significantly increasing the size of its current facility and adding cell and gene therapy (CGT) testing to the operation’s portfolio of services.
Last month saw ATMPS Ltd, a developer of blockchain-based cell orchestration platforms for advanced therapies, and Ori Biotech, an innovator in cell and gene therapy (CGT) manufacturing platforms, come together in an alliance aimed at creating seamless...
Efficiency in the biopharmaceutical space has never been more top-of-mind. The COVID-19 pandemic brought an unprecedented urgency to R&D and the key players delivered: Several groups produced a vaccine in record time. To maintain and improve on this...
Driven by encouraging clinical trial data, and a growing demand for effective and personalized therapeutic modalities, the CGT services market is anticipated to witness significant development, growing at a CAGR of over 25% up to 2030, forecasts a new...
Cell and Gene Therapy Catapult (CGT Catapult) says that GSK will leverage its Stevenage facility to perform GMP cell processing and accelerate its cell and gene therapy pipeline for clinical trials.
China's Pharmaron has entered into a definitive agreement to acquire the Allergan Biologics Limited (ABL) site in Liverpool, UK, for US$118.7m in cash from AbbVie.
The number of advanced therapy medicinal product (ATMP) clinical trials in the UK continues to increase year on year with 154 ongoing trials observed in 2020, demonstrating the appeal of that market for the clinical development of ATMPs, shows a new report.
WuXi AppTec has completed its acquisition of Oxgene, a UK contract research and development organization that designs and develops scalable gene therapy technologies.
Massachusetts-based clinical research organization (CRO), Charles River Laboratories, is to acquire Cognate BioServices, a cell and gene therapy contract development and manufacturing organization (CDMO) for around US$875m in cash.
Global CDMO, Rentschler Biopharma, has announced today that it will build its ATMP capacity in the UK at the Cell and Gene Therapy (CGT) Catapult facility in Stevenage.
The growing global pipeline of cell and gene therapy projects has prompted Thermo Fisher Scientific to invest again, with it announcing today that it had bought Henogen, Novasep’s viral vector manufacturing business based in Belgium, for about US$879.72m...
Preclinical contract research organization (CRO), Charles River Laboratories International, has announced the acquisition of an antibody discovery company, Distributed Bio, for US$83m in cash.
US headquartered company, Orgenesis, and South Korea-based, Cure Therapeutics, have signed a JV deal to advance the development, regulatory approval, and commercialization of point of care production for both companies’ cell and gene therapies and immunotherapies....
New data shows a move towards commercialization and a 48% increase in GMP cell and gene therapy (CGT) manufacturing space in the UK this year despite the COVID-19 pandemic.
Bayer will broaden its innovation base in cell and gene therapy with the acquisition of Asklepios BioPharmaceutical (AskBio): a US biotech working in gene therapies across different therapeutic areas.
Ori Biotech Ltd (Ori), a London and New Jersey based innovator in the cell and gene therapy (CGT) manufacturing sphere, last week announced the successful close of a US$30m Series A financing round, bringing the company’s total funding to date to US$41m.
German life science company Sartorius will merge Slovenian purification specialist BIA Separations with Sartorius Stedim Biotech, in a deal worth €360m ($423m).
Increased manufacturing demands for cell and gene therapies drive the growth of the viral vector supply market, but challenges are still to be addressed, says Symbiosis.
Frontage has announced completion of its Pennsylvania site expansion to boost its offering of bioanalytical services for late-stage cell and gene therapies developers.
The Alliance for Regenerative Medicine publishes a cross-border healthcare plan, which would enable ‘timely and effective’ access to ATMPs for patients in Europe.
With the number of roles in manufacturing projected to rise by 196% over the next five years, industry fears a lack of expertise to fill vacuum, according to survey.
ACG Inspection’s CEO talks about a ‘fear’ of the disruption caused by advanced medicine, which prevents big pharma companies from investing in the supply chain.
Modifications on the regulatory framework and focus on funding schemes are the first steps on the path for healthcare systems to adapt to ATMPs’ ‘new ground’, says ARM head for Europe.
Early dialogue with patients is ‘critical’ to design efficient clinical development programs for ATMPs and avoid ‘data gaps’, an executive from ARM says.
Cellectis chooses Lonza to take on the clinical manufacturing of its UCART blood cancer immunotherapy candidates, intended to be marketed as industrialized, readily available CAR-T cells.
The seventh #NLSDays event saw the latest trends in fields including ATMP, clinical evolution, and R&D technologies, find their audience in Scandinavia.
The increasing number of cell and gene therapies in clinical development is evolving the supply chain into a ‘supply cycle,’ says TrakCel CEO, with service providers being called to maintain control under pressure.
The global market for regenerative medicines raised $4.8bn in the first half of 2019; a slowdown compared to the same period of 2018, though the sector is poised for additional growth, says ARM CEO.
Lonza enters a partnership with Vineti to advance its ‘vein-to-vein’ delivery network, creating an end-to-end ordering and manufacturing process in support of cell and gene therapy development.
CGT Catapult reports that employment has increased substantially, and production capacity has grown by 60% in the UK cell and gene therapy manufacturing industry.
